title: [Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin].
abstract: A total of 465 patients with primary and multiple or recurrent, stages Ta and T1 superficial bladder cancer were included in this randomized multicenter trial to compare the prophylactic effect by 17 times instillation of 40 mg doxorubicin or 40 mg epirubicin with no instillation after transurethral resection of tumor(s). The primary endpoint was first recurrence after transurethral resection. Endoscopic examination as well as urinary cytology was performed in each case every three months. It became evident that the recurrence rate in the doxorubicin or epirubicin instillation arm was lower that in the no instillation arm. Toxicity was mainly restricted to bladder irritation in about 10% of patients in each instillation arm.
authors.affiliation: Faculty of Medicine, University of Tokyo.
authors.forename: Shiro
authors.initials: S
authors.lastname: Hinotsu
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Akaza
authors.forename: Shigeo
authors.initials: S
authors.lastname: Isaka
authors.forename: Susumu
authors.initials: S
authors.lastname: Kagawa
authors.forename: Kenkichi
authors.initials: K
authors.lastname: Koiso
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Kotake
authors.forename: Toyohei
authors.initials: T
authors.lastname: Machida
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Matsumura
authors.forename: Tadao
authors.initials: T
authors.lastname: Niijima
authors.forename: Koji
authors.initials: K
authors.lastname: Obata
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ohashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ohe
authors.forename: Jun
authors.initials: J
authors.lastname: Shimazaki
authors.forename: Kazuya
authors.initials: K
authors.lastname: Tashiro
mesh_terms: D000283:Administration, Intravesical; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007322:Instillation, Drug; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011182:Postoperative Care; D001749:Urinary Bladder Neoplasms / Q000517:prevention & control* / Q000601:surgery
chemical_list: D015251:Epirubicin; D004317:Doxorubicin